Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
Clinical trial NCT05349838 · COMPLETED
Trial details
- NCT number
- NCT05349838
- Sponsor
- NEAT ID Foundation
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-05
- Primary completion
- 2021-11-15
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.